David Solit
大卫·索利特
MD
Director, Center for Molecular Oncology分子肿瘤学中心主任
👥Biography 个人简介
David Solit leads precision oncology at MSKCC, directing the MSK-IMPACT tumor sequencing program. His research deciphers oncogenic signaling pathways, including RAS/RAF, to match patients with targeted therapies and understand acquired resistance mechanisms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MSK-IMPACT Clinical Sequencing Program
Led development and clinical implementation of MSK-IMPACT, a comprehensive tumor sequencing panel enabling precision matching of patients to targeted therapies at scale.
RAS/RAF Signaling and Resistance
Elucidated mechanisms of intrinsic and acquired resistance to BRAF and MEK inhibitors, guiding rational combination strategies to overcome resistance in solid tumors.
Representative Works 代表性著作
BRAF mutation predicts sensitivity to MEK inhibition
Nature (2006)
Demonstrated that BRAF-mutant cancers are selectively sensitive to MEK inhibition, supporting biomarker-driven clinical trials for RAF/MEK inhibitors.
Prospective genomic profiling with MSK-IMPACT
Nature Medicine (2017)
Reported clinical results of large-scale tumor sequencing, demonstrating actionable alterations in the majority of advanced cancer patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 大卫·索利特 的研究动态
Follow David Solit's research updates
留下邮箱，当我们发布与 David Solit（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment